10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. decreased its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 32.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 651,582 shares of the company’s stock after selling 313,100 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.54% of 10x Genomics worth $14,713,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Primecap Management Co. CA grew its holdings in 10x Genomics by 58.1% in the 3rd quarter. Primecap Management Co. CA now owns 295,400 shares of the company’s stock worth $6,670,000 after buying an additional 108,600 shares in the last quarter. First Horizon Advisors Inc. boosted its position in 10x Genomics by 53.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 2,910 shares of the company’s stock worth $66,000 after acquiring an additional 1,012 shares during the period. Commerce Bank grew its stake in shares of 10x Genomics by 17.1% in the third quarter. Commerce Bank now owns 13,296 shares of the company’s stock worth $300,000 after purchasing an additional 1,946 shares in the last quarter. LMR Partners LLP acquired a new position in shares of 10x Genomics during the third quarter valued at $1,587,000. Finally, KBC Group NV raised its stake in shares of 10x Genomics by 38.8% during the third quarter. KBC Group NV now owns 3,225 shares of the company’s stock valued at $73,000 after purchasing an additional 902 shares in the last quarter. Institutional investors own 84.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on TXG shares. Morgan Stanley lowered their target price on shares of 10x Genomics from $50.00 to $46.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th. Canaccord Genuity Group dropped their target price on 10x Genomics from $32.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, October 10th. Barclays decreased their price target on 10x Genomics from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Leerink Partnrs raised 10x Genomics to a “strong-buy” rating in a research note on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. cut their price objective on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a report on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $29.19.

10x Genomics Stock Up 4.2 %

TXG opened at $15.87 on Friday. 10x Genomics, Inc. has a 12-month low of $12.95 and a 12-month high of $57.90. The business has a 50 day moving average of $16.25 and a 200-day moving average of $19.26. The stock has a market cap of $1.92 billion, a price-to-earnings ratio of -10.37 and a beta of 1.84.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings results on Tuesday, October 29th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.04. The firm had revenue of $151.65 million for the quarter, compared to analysts’ expectations of $158.84 million. 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. The business’s revenue was down 1.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.51) EPS. As a group, analysts expect that 10x Genomics, Inc. will post -1.4 earnings per share for the current year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.